8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934



                                  June 23, 2006
                Date of Report (Date of earliest event reported)



                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)



           DELAWARE                  000-29089                06-1562417
 (State or other jurisdiction       (Commission             (IRS Employer
        of incorporation)           File Number)         Identification No.)

        630 Fifth Avenue, Suite 2100
              New York, NY 10111                               10111
   (Address of principal executive offices)                 (Zip Code)

                                  212-994-8200
              (Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[_]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[_]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))






Item 7.01   Regulation FD Disclosure

On June 23,  2006,  Antigenics  Inc.  announced  that a purported  class  action
complaint was filed on June 16, 2006 in the United States District Court for the
District of New Mexico by Steven J. Tuckfelt on behalf of himself and all others
similarly situated against Antigenics Inc. and our chief executive officer, Garo
H. Armen,  PhD. The full text of the press release issued in connection with the
announcement  is being  furnished as Exhibit 99.1 to this current report on Form
8-K.



Item 9.01 Financial Statements and Exhibits


         (d) Exhibits


The following exhibit is furnished herewith:

99.1 Press Release dated June 23, 2006







                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                             ANTIGENICS INC.

Date: June 23, 2006
                             By: /s/ Garo H. Armen
                             ------------------------------------
                             Garo H. Armen, Ph.D.
                             Chairman and Chief Executive Officer






                                 EXHIBIT INDEX


Exhibit No.       Description of Exhibit

99.1              Press Release dated June 23, 2006

EX-99.1

                                                                    Exhibit 99.1

                   Antigenics Believes Class Action Litigation
              is without Merit and Intends to Defend It Vigorously


    NEW YORK--(BUSINESS WIRE)--June 23, 2006--Antigenics Inc. (NASDAQ:
AGEN) today announced that on June 16, 2006, a purported class action
complaint was filed in the United States District Court for the
District of New Mexico by Steven J. Tuckfelt on behalf of himself and
all others similarly situated against Antigenics Inc. (the "Company")
and its chief executive officer, Garo H. Armen, PhD. The complaint
alleges that certain disclosures by the Company violated Sections
10(b) and 20(a) of the Securities and Exchange Act of 1934 as well as
includes purported claims for breach of fiduciary duty.
    The Company believes that the complaint is without merit and plans
to vigorously defend against the litigation. The Company's policy is
to not discuss pending litigation.
    Antigenics is a biotechnology company working to develop
treatments for cancers, infectious diseases and autoimmune disorders.
For more information, please visit www.antigenics.com.

    Forward-Looking Statements

    Some statements in this press release are known as
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. These forward-looking statements include statements about the
Company's beliefs and intentions regarding the reported lawsuit.
Because these forward-looking statements involve known and unknown
risks and uncertainties, there are important factors that could cause
actual results, events or developments to differ materially from those
expressed or implied by these forward-looking statements, including a
ruling by a court that is adverse to the Company's position and other
uncertainties and matters beyond the Company's control inherent in
legal proceedings. These forward-looking statements are based on the
information currently available to the Company and speak only as of
the date of this press release. The Company disclaims any obligation
to update any forward-looking statements, whether as a result of new
information, future events or otherwise.



    CONTACT: Antigenics Inc.
             Investor Relations:
             Shalini Sharp, 800-962-2436
             ir@antigenics.com
             or
             Media Relations:
             Sunny Uberoi, 917-443-3325
             suberoi@antigenics.com